Skip to main content

1.4 UNMC Ceding Review to an External Central IRB

1.0 Purpose

The purpose of this policy and procedure is to describe the Organization’s requirements for the UNMC IRB to cede review to an external IRB.

2.0 Policy

  • 2.1. It is the policy of the Organization that all non-exempt research under the authority of the UNMC IRB and conducted, supported, or otherwise subject to regulation by any Federal department or agency which has adopted the Common Rule will rely on upon approval by a single IRB for that portion of the research that is conducted in the United States, in accordance with 45 CFR 46.114, unless excluded from this requirement under 45 CFR 46.114(b)(2).
  • 2.2. It is the policy of the Organization that all NIH-funded research will rely on upon approval by a single IRB, in accordance with the NIH Policy on the Use of a Single Institutional Review Board for Multi-Site Research (NOT-OD-16-094), unless excluded from this requirement under NIH policy (NOT-OD-18-003).
  • 2.3. It is the policy of the Organization that selected independent commercial IRBs may serve as the IRB of record as permitted by HHS regulations at 45 CFR 46.114 and FDA regulations at 21 CFR 56.114 for new commercially sponsored clinical trials, with the exceptions specified under Section 2.5 below.
  • 2.4. It is the policy of the Organization that the National Cancer Institutes (NCI) Central IRBs (CIRBs) may serve as the IRB of record for pediatric and adult research sponsored by the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) as permitted by HHS regulations at 45 CFR 46.114 and FDA regulations at 21 CFR 56.114.
  • 2.5. It is the policy of the Organization that other external IRBs may serve as the IRB of record as permitted by HHS regulations at 45 CFR 46.114 and FDA regulations at 21 CFR 56.114 on a case-by-case basis, with the exceptions specified under Section 2.5 below, provided the following conditions are met:
    • 2.5.1. For research which constitutes greater than minimal risk, the external IRB is part of an accredited HRPP or has completed the OHRP QA Self-Assessment Tool
    • 2.5.2. For research which constitutes no more than minimal risk, the external IRB reviews the research appropriately, in compliance with all federal, state, and local regulations, and the review criteria utilized by the external IRB are in compliance with the Organization’s ethical standards and with applicable laws and regulations, and with the specific approval of the IO, in consultation with the IRB Executive Chair as appropriate.
    • 2.5.3. The external Institution has a valid FWA, and the external IRB is registered with OHRP and FDA (as applicable).
  • 2.6. It is the policy of the Organization that, unless use of a single IRB subject is required by 45 CFR 46.114, or required by NIH policy, the use of an external IRB is not permitted for:
    • 2.6.1. Clinical trials initiated by a UNMC investigator
    • 2.6.2. Use of a Humanitarian Use Device (HUD) subject to 21 CFR 814.124(a)
    • 2.6.3. Emergency research subject to FDA regulations at 21 CFR 50.24.
    • 2.6.4. Research that involves the use of vaccines developed or manipulated at UNMC.
    • 2.6.5. Research involving gene transfer.
    • 2.6.6. Emergency use of a test article subject to FDA regulations at 21 CFR 56.102(d) and 21 CFR 56.104(c).
    • 2.6.7. Research involving prisoners as subjects.
    • 2.6.8. Research involving fetal tissue or HESCs, or their derivatives
  • 2.7. It is the policy of the Organization that the IO, in consultation with the IRB Executive Chair as appropriate, has the sole authority to determine whether or not to allow the UNMC IRB to cede review of research described in 2.5 to an external IRB.
  • 2.8. It is the policy of the Organization that the IO, in consultation with the IRB Executive Chair as appropriate, has the sole authority to allow exceptions to the exclusions in 2.6 above.
  • 2.9. It is the policy of the Organization that it will accept the review and approval of an external IRB for human subject research exempt under 45 CFR 46.104; however, the Organization will not require the execution of a Reliance Agreement.
  • 2.10. It is the policy of the Organization that there must be an executed Reliance Agreement between UNMC and the external IRB’s institution or the commercial IRB, prior to utilization of the external or commercial IRB, for all non-exempt research.
  • 2.11. It is the policy of the Organization that all Organizational review requirements must be completed and the Reliance Agreement be fully executed before the research will be released to the external or commercial IRB, for all non-exempt research; however the IO and Executive Chair have the authority to allow exceptions to this policy.
  • 2.12. It is the policy of the Organization that the research may not commence until approval has been granted by the external IRB.
  • 2.13. It is the policy of the Organization that research conducted under the purview of an external IRB will be subject to all relevant policies of the external (reviewing) IRB, and investigators of the Organization must comply with those policies, except as specified in addendum 2.
  • 2.14. It is the policy of the Organization that investigators must comply with Organization policies as described in Addendum 2.
  • 2.15. It is the policy of the Organization that all research conducted under an external IRB is subject to post approval monitoring per HRPP policy 1.21 (Post-Approval Monitoring of Research).

3.0 Definitions

  • 3.1. Cede Review: The Organization has agreed to transfer IRB review and oversight authority for specified research to another institution’s IRB (reviewing or external IRB)
  • 3.2. Reliance Agreement (also known as an Authorization Agreement): An agreement between two Organizations engaged in human subject research that documents respective authorities, roles, responsibilities, and communication between an organization between the reviewing and relying IRBs.
  • 3.3. Relying Institution: A participating Institution that cedes IRB review to the IRB of record (reviewing IRB) designated under a Reliance Agreement.
  • 3.4. Reviewing IRB (or External IRB): The IRB which is responsible for conducting IRB review and approval as described in 45 CFR 46.109 for cooperative human subject research. For the purpose of this policy, reviewing IRB and external IRB are the same.

4.0 External IRB, UNMC IRB, and PI Responsibilities

  • 4.1. It is the responsibility of the external IRB (as reviewing IRB) to:
    • 4.1.1. EnsureConduct review of the research in full accordance with applicable federal and state regulations, and all investigatorsrelevant policies of the external IRB (including, but not limited to, initial review, continuing review, review of amendments, noncompliance, unanticipated problems involving risk to subject or others, deviations, adverse events, study holds, suspensions, and research staff have the appropriate qualifications and expertise to conduct the research, are knowledgeable about laws, regulations, codes and guidance governing their research, and are knowledgeable about the Institutions policies and procedures.terminations).
    • 4.1.2. The external IRB is responsible for obtainingObtain any additional approvals from DHHS when the research involves pregnant women, fetuses, and neonates; or children; or prisoners (as applicable per DHHS and FDA regulations).
    • 4.1.3. The external IRB is responsible for reportingReport all determinations of serious or continuing noncompliance, unanticipated problems involving risk to the subject or others, and suspensions or terminations to the Relying Institution, Institutional Officials and Federal Agencies.
    • 4.1.4. Report to the UNMC IRB:
      • 4.1.4.1. Any unanticipated problems involving risk to the subject or others associated with subjects enrolled at the institution.
      • 4.1.4.2. Any serious or continuing noncompliance.
      • 4.1.4.3. Any serious complaints which impact the rights and welfare of research subjects.
      • 4.1.4.4. The results of any external audits conducted by FDA, OHRP, sponsors, and CROs.
      • 4.1.4.5. Any reports filed with the FDA or OHRP.
      • 4.1.4.6. Any FDA Form 483 or warning letter pertaining to the study or IRB review.
      • 4.1.4.7. Any other communication from FDA or other governmental agency citing improper or inadequate research practices.
    • 4.1.5. Notify the Investigator and the Institution (when applicable) of the IRB’s determinations.
    • 4.1.6. Provide a Point of Contact (POC) and contact information for UNMC researchers and research staff to obtain answers to questions, express concerns, and convey suggestions regarding the use of the external IRB.
    • 4.1.5.7. ReportUpon written request, provide UNMC with access to therelevant UNMCrecords IRB:
      • 4.1.5.1. Any unanticipated problems involving riskrelated to theIRB subjectreview or(including, othersbut associatednot withlimited subjectsto enrolledminutes, atapproved thisprotocols, site.
        • consent
      • 4.1.5.2.forms, Anyand seriousother orrecords continuingthat noncompliance.
      • 4.1.5.3. Any serious complaints which impactdocument the rightsIRB’s and welfare of research subjects.
      • 4.1.5.4. The results of any external audits conducted by FDA, OHRP, sponsors, and CROs.
      • 4.1.5.5. Any reports filed with the FDA or OHRP.
      • 4.1.5.6. Any FDA 483 or warning letter pertaining to the study or IRB review.
      determinations).
  • 4.2. It is the responsibility of the UNMC IRB toand adviseHRPP (on behalf of the externalrelying IRBinstitution) of:to:
    • 4.2.1. AnyAdvise the external IRB of any applicable state or local laws governing research conducted at this Organization.
    • 4.2.2. Advise the external IRB of the resultscompletion of all additional reviews conductedrequired atby the Relying Institution, including but not limited to biosafety review, radiation safety review, recombinant DNA research review, human stem cell research review and conflict of interest.
      • 4.2.2.1. Educate the investigatorsinterest, and research personnel at the Relying site of any requirements resulting from the additional Institutional reviews.
    • 4.2.3. Advise the external IRB of any circumstances when the review must take into account additional regulatory requirements or local HRPP requirements.
    • 4.2.4. TheEnsure that all investigators participating in the research are members of the Institution’s medical staff in good standing and are credentialed and privileged to perform the procedures outlined in the studies.
      • 4.2.4.1. Notify the external IRB of the termination, suspension, or modification of any clinical privileges of the OrganizationsOrganization’s investigators.Medical Staff who are participating in the studies authorized by the external IRB.
    • 4.2.5. AnyAdvise the external IRB of any allegations of noncompliance which are received by the ORA.ORA and which are found to be serious or continuing, or which represent an unanticipated problem involving risk. The external IRB, in conjunction with the ORA, will determine how best to handle the allegation in consideration of the need to maintain due process and protect the whistleblower.
    • 4.2.6. AnyAdvise the external IRB of any complaint directly from subjects or others. The Research Subject Advocate Office will assist in the resolution of the complaint as necessary.
    • 4.2.7. AnyAdvise the external IRB of any contact by the FDA, HHS, or any other persons or entities regarding the research.research within three business days of contact.
    • 4.2.8. Notify the external IRB within three business days, in the event that the FDA or other governmental agency issues the relying Institution any “Notice of Inspectional Observations”, “Warning Letters”, or other communications citing improper or inadequate research practices with respect to the research specified above.
    • 4.2.9. Ensure that all investigators participating in the research understand their responsibilities under applicable federal regulations (45 CFR 46 including subparts as applicable, 21 CFR 50, 56, 312, 812, and HIPAA Privacy Rule), state laws, institutional policies, and the protocol.
    • 4.2.10. Ensure that all research personnel involved in the process of consent or assent are properly trained and are fully aware of their responsibilities relative to the obtainment of informed consent/assent according to institutional policies, applicable federal regulations, and state law.
  • 4.3. It is the responsibility of the UNMC PI’s responsibilityPI to:
    • 4.3.1. Complete all requirements for submission of request to utilize the CIRB to the ORA.
    • 4.3.2. Complete all requirements for submission to the external IRB.
    • 4.3.3. Comply with all relevant UNMC HRPP policies, such as, but not limited to, those related to compensation, advertisement, ethical access, short form consent, process and documentation of consent.
    • 4.3.4. Comply with all determinations and requirements of the external IRB.
    • 4.3.4.5. Comply with the external IRB’s requirements for initial and continuing review, record keeping, and reporting in a timely manner.
    • 4.3.5.6. Promptly report the following to the external IRB (in accordance with their policies):
      • 4.3.5.6.1. Any proposed changes to the research. The investigator cannot implement changes to the research (including changes in the consent form) without prior IRB approval except where necessary to eliminate apparent immediate hazard to subjects.
      • 4.3.5.6.2. Conflict of interest (COI) management plans (in accordance with HRPP policy #1.25:25: Financial Conflicts of Interest). The UNMC PI and research staff must comply with all determinations. Note: The external IRB may impose additional safeguards; however, the external IRB may not be less stringent than what is required by the UNMC COI management plan.
      • 4.3.5.6.3. Incidents of noncompliance. Copies of all reports to the federal government (e.g., OHRP, FDA, federal sponsor or funding agency) must also be provided to the UNMC IRB administrator.ORA.
      • 4.3.5.6.4. Protocol deviations.
      • 4.3.5.6.5. Any complaints from subjects or others. The UNMC Research Subject Advocate Office will assist in the resolution of the complaint as necessary.
      • 4.3.5.6.6. Data Safety Monitoring Reports
    • 4.3.6.7. Promptly report to the external IRB (in accordance with their policies) and the ORA any internalInternal adverse events and other events which qualify as an unanticipated problem involving risk to the subject.
  • 4.3.7. NotifyPromptly report to the ORAUNMC whenIRB there
    • 4.3.7.1. areAny changesnew or modified conflicts of interest of responsible personnel (per HRPP policy 1.25 [Financial Conflicts of Interest]), and any new or modified management plans.
    • 4.3.7.2. Additional requirements by the external IRB to the UNMC COI management plan.
    • 4.3.7.3. Incidents of non-compliance
    • 4.3.7.4. Copies of all reports to OHRP and/or FDA.
    • 4.3.7.5. Reports of internal adverse events
    • 4.3.7.6. Changes in study personnel
      • so that human subject protection training and conflict of interest may be reviewed in accordance with Organizational policy.
  • 4.3.8. Ensure all investigators and research staff have the appropriate qualifications and expertise to conduct the research.
  • 4.3.9. Ensure that all research personnel understand their responsibility in enrolling participants in the research; including obtainment, documentation, and maintenance of records of consent for each subject/LAR.
  • 4.3.9.10. ConductingConduct monitoring in addition to, or in cooperation with, the external IRB.IRB and the ORA.
  • 4.3.10.11. Notify the ORA when a study is completed. The date of completion will be entered into the IRB database and the study will be reclassified as “completed”.completed
  • 4.4. There may be additional external IRB, UNMC IRB, and PI, responsibilities dictated by the IRB Reliance Agreement. The fully executed IRB Reliance Agreement must be maintained as documentation verifying the responsibilities of each organization to ensure compliance with the requirements of the Common Rule.

    • 5.0 Procedures

    • 5.1. TheFor all non-exempt human subject research, the PI must submit the applicationCentral CIRBIRB ReviewApplication of Research(CIRB) through RSS (https://net.unmc.edu/rss). The application must be accompanied by the following documents:

      • 5.1.1. Full protocol

      • 5.1.2. Sponsor’s template consent forms and/or information sheets

      • 5.1.3.Note Clinical Trial Master Matrix

      • 5.1.4. Pharmacy & Therapeutic Committee Drug Registry Forms, if applicable

      • 5.1.5. Recruitment materials (such as fliers and brochures, text of radio and TV advertisements)

        Note:: It is recommended that the PI contact the ORA to determine if the proposed research will qualify for external IRB review prior to submission of the application. Acceptance of the application by the ORA does not signify that review will be ceded.

    • 5.2. The IRB Administrator must determine that the request to utilize an external IRB satisfies the requirements of SectionsSection 2.1, 2.2, 2.3 or 2.4, and not excluded by 2.52 above. The administrator, in consultation with the Executive ChairChair, as appropriate, will then present to the IO the request to allow the UNMC IRB to cede IRB review to the external IRB.
    • 5.3. If the IO approves the request, the UNMC IRB Administrator will review the “CIRBCentral ReviewIRB of Biomedical Research” applicationApplication” to determine that:

      • 5.3.1. The research satisfies UNMC requirements including, but not limited to:

        • 5.3.1.1. Subject payment; per HRPP policypolicies 3.8as (Researchdescribed Subjectin Compensation)addendum 2.
        • 5.3.1.2. Contraception; per HRPP policy 3.9 (Contraception Requirements)
        • 5.3.1.3. Subject identification and recruitment; per HRPP policies 3.5 (Subject Recruitment through Advertisements) and 3.6 (Subject Recruitment Through Direct Invitation), including ethical access (HRPP policy 3.12).
        • 5.3.1.4. Investigator and research staff training; per HRPP policy 1.23: HRPP Training Requirements and Opportunities for Research Personnel)
        • 5.3.1.5. Review and approval by other components of the HRPP (including, as appropriate, Conflict of Interest Committee, Fred & Pamela Buffett Cancer Center Scientific Review Committee, Pharmacy & Therapeutics Committee, Investigational Device Review Committee, Pathology, IT Security if SSNs maintained)
        • 5.3.1.6.3. Contract review by Sponsored Programs Administration or UNeHealth
        • 5.3.1.7.4. Coverage analysis and matrix/study calendar

      • 5.3.2. Appropriate agreements are in place, including, but not limited to:

        • 5.3.2.1. Executed sponsored agreement
        • 5.3.2.2. Data Use, Data Transfer and/or Material Transfer Agreements
        • 5.3.2.3. IRB Reliance Agreement between UNMC IRB and external IRB

      • 5.3.3. The UNMC IRB Administrator will issue a conditional acceptance letter to the investigator, conditionalwith on any required modificationsconditions based on Organizational requirements.

      • 5.3.4. The UNMCfollowing Administratoritems willare supplyavailable to theinvestigators investigatorand the following items, tomay be provided to the external IRB:

        • 5.3.4.1. UNMC CFConsent Form letterhead (use recommended but not required).
        • 5.3.4.2. The UNMC Addendum CF containing required consent form language as(addendum per addendum1 to this policy. The external IRB may, at its discretion, merge the required UNMC CF language into the main CF.policy).
        • 5.3.4.3. Any COI management plan and the potential impact on the protocol (for example, prohibiting the PI from obtaining informed consent) orincluding any requirements for disclosure in the informed consent form.
        • 5.3.4.4. Additional information related to local context issues, including state, local or institutional regulations or policies that may impact IRB review.
      • 5.3.4.5. Updates to all local context issues as applicable.

    • 5.3.5. When the external IRB has completed its review, the approved CF language must be placed on UNMC letterhead. The UNMC IRB Administrator will review CF to assure inclusion of required language.

    • 5.3.6. Once all Organizational requirements have been met (as specified in HRPP policy 2.2; Section 8.0: Full IRB Review and HRPP policy 2.3; Section 13.0: Expedited ReviewReview) and the IRB Reliance Agreement is fully executed, the IRB Administrator will provide the PI with an acceptance letter granting acceptance of IRB oversight by the external IRB.

    • 5.3.7.6. The study may not be initiated until the acceptance letter has been provided to the PI.
      Note:Note: Once it has been determined that an external IRB will serve as the IRB of record for any given study, all communications from the PI and other study personnel regarding IRB review of the study or its status must be with the external IRB, except as specified in Sections 4.3.6, 4.3.7, and 4.3.87 above. UNMC IRB staff do not have the authority to respond to questions or concerns on behalf of the external IRB.

      Note:*Note: The external IRB policies and procedures for stamping (or not stamping) consent forms with the approval dates take precedence. The UNMC IRB will not review or provide an approval stamp on any consent forms or information sheets approved by an external IRB.

      *

  • 5.3.8.4. TheFor fullresearch UNMCexempt IRBunder will45 beCFR notified46.104, a copy of the acceptanceprotocol ofand application submitted to, and approved by the external IRB review(or andHRPP) approvalwill be accepted by the ORA in lieu of the researchCentral IRB Application.

    • 5.4.1. The IRB administrator will review submitted materials as a special notification itemdescribed in HRPP Policy 2.6 (Exempt Research).
    • 5.4.2. If acceptable, the IRBprotocol agendawill be designated “ET” and minutes.

      will otherwise be handled as an “EX” protocol.

  • 5.3.9.5. The ORA, the IRB and the IO retain the authority to suspend research conducted within the organization which has been ceded to an external IRB, if the ORA, IRB or IO believes such action is necessary to protect the rights and welfare of human subjects of the research. The suspension will be promptly reported to the external IRB.

    • ADMINISTRATIVE APPROVAL:

    • BRUCE G. GORDON, MD — IRB EXECUTIVE CHAIR & ASSISTANT VICE CHANCELLOR FOR REGULATORY AFFAIRS
    • CHRISTOPHER KRATOCHVIL, MD — INSTITUTIONAL OFFICIAL

    POLICY AMENDED:

    • REVISED OCTOBER 21, 2021Added organizational policy to comply with Common Rule and NIH requirements regarding use of a single IRB; deleted redundant policy statements; clarified requirements for accreditation of reviewing IRB; modified types of research not eligible for use of external IRB; moved list of UNMC policies that must be followed to addendum 2; clarified responsibilities of external IRB, UNMC IRB and investigators; clarified ORA and IRB procedures; clarified required documents to be submitted by PI; other minor reorganization of policy; added Addendum 1 and 2.
    • REVISED FEBRUARY 28, 2018

    • REVISED MAY 30, 2017

    Addendum:Addendum 1: UNMC Required Consent Form Language

    1. What

      Title: will
      beingAs inthe thisIRB researchof studyrecord costallows, you?the [Thisconsent sectionForm should describeappear theon financialUNMC/ obligationsNebraska theMedicine subjectletterhead willfor incureasy identification as a resultresearch ofconsent participatingform. The UNMC IRB number should appear in the studyconsent.

      and

      Contraception/Pregnancy whether any financial obligations will be increased as a result of procedures performed solelyLanguage for researchFDA purposes.]

    You will be responsible for any applicable insurance deductibles and co-payments. If you wish to speak with a financial counselor about your insurance coverage and benefits, let the investigator or other study personnel know. A contact for personal assistance will be made available for you.

    [If there are no financial obligations, use only the following clause] There is no cost to you to be in thisregulated research study.

    1. Who is paying for this research study?

    [For commercially supported studies]: The sponsor of the research is [name of sponsor]. [Name of Institution; Nebraska Medicine, UNMC, CHMC and/or UNO] receives money from the sponsor to conduct this study.

    [For studies supported by research grants]: This research is being paid for by [name of granting agency]. The Institution receives money from [name of granting agency] to conduct this study.

    [For NIH funded cooperative group studies]: The Institution receives money from [name of cooperative group] to conduct this study.

    [For studies without external support, include as applicable]: This research is being paid for by [for example, the Department of Internal Medicine, Section of Oncology of the University of Nebraska Medical Center].

    [If required by the institution, the PI will be directed to add any required financial conflict of interest statement here.]

    1. What are the pregnancy risks associated with this study? Insert appropriate contraception language based on FDA Pregnancy and Lactation Labeling Rule and/or FDA Use-In-Pregnancy category, as per HRPP Policy 3.9 (Contraception Requirements)

      2. Category

    2. A

      Whatand shouldSome youCategory B Drugs (do not require contraception) It is possible that the medicines used in this study could injure a fetus if you or your partner becomes pregnant while taking them. You have already been told what is known about this possibility, and you are injuredencouraged to ask further questions.

      Category B, C and D Drugs It is possible that the medicines used in this study could injure a fetus if you or your partner becomes pregnant while taking them. You have already been told what is known about this possibility, and you are encouraged to ask further questions.

      You may want to discuss this with others before you agree to take part in this study. If you wish, we will arrange for a doctor, nurse, or counselor who is not part of this study to discuss the potential risks and benefits with you and anyone else you want to have present.

      Because of the potential risks, you or your partner must not become pregnant while participating in this study. Women must have a medicalnegative problempregnancy duringtest thisbefore research study? Your welfare isentering the mainstudy concern(and ofbefore everyeach membertreatment ofas theappropriate).

      research team.

      If you are injuredsexually active and can get pregnant, or havecan aget medicalyour problempartner aspregnant, ayou directmust resultuse ONE (or TWO) appropriate method of beingbirth incontrol every time you have sex, or you must not have sex.

      You can get additional information about methods to avoid pregnancy by calling the UNMC Research Subject Advocate's Office at (402) 559-6941.

      You or your partner will need to continue to avoid pregnancy for X months after finishing the research.

      Should you or your partner become pregnant while on this study, you should immediately contactnotify onethe study personnel. The investigator will assist you in finding appropriate medical care. The investigator also may ask to be allowed to continue getting information about your pregnancy. You can refuse to provide this information.

      Category X drugs: Since studies of the peopledrug listedin humans, or investigational or post-marketing data, have demonstrated fetal risk, contraception is required and the language must be at least as protective as Category D language above. Often the endsponsor and/or FDA require inclusion of thisspecific language relating to fetal risk, monitoring for pregnancy and prevention of pregnancy in the consent form. EmergencyThe medicallanguage treatmentcannot forbe thismodified.

      injury

      Subject Injury Language for greater than minimal risk research Add the following to consent form subject injury language:

      UNMC and Nebraska Medicine [or Children’s Hospital Medical Center]. If there is not sufficient time, you should seek care from a local health care provider.

    The Institution has no plans to pay for any required treatment or provide other compensation. If youthe havesubject has insurance, yourthe insurance company may or may not pay the costs of medical treatment. If youhe/she dodoes not have insurance, or if yourthe insurance company refuses to pay, you will be expected to pay for the medical treatment.

    Agreeing to this does not mean you have given up any of your legal rights.

    1. HIPAA

      HowLanguage willAdd information about you be protected? In additionthis to the informationHIPAA givenlanguage:

      to
      • you in the main consent form, we

        We may share information about you with other groups:

        •
        • The UNMC Institutional Review Board (IRB)
          • •
        • Institutional officials designated by the UNMC IRB
          • [
        • (if the research involves patients with cancer]:cancer, •add the following) The Fred & Pamela Buffett Cancer Center Scientific Review Committee (SRC)

      • WhatInformation arerelated yourto subject rights asshould ainclude researchthe subject?UNMC You have rights as a research subject. These rights have been explained in this consent formIRB and in “ The Rights of Research Subjects”Subject andAdvocate “ What Do I Need to Know” handout that you have been given. If you have any questions concerning your rights or want to discuss problems, concerns, obtainContact information

        or offer input, or make a complaint about the research, you can contact any of the following:
        •
        • The investigator or other study personnel
          • • [insert contact information for CIRB] • UNMC
        • Institutional Review Board o(IRB)Telephone: (402) 559-6463 o6463Email: IRBORA@unmc.edu oeduMail: UNMC Institutional Review Board, 987830 Nebraska Medical Center, Omaha, NE 68198-7830
          • • UNMC
        • Research Subject Advocate oTelephone: (402) 559-6941 o6941Email: unmcrsa@unmc.edu

      Addendum 2: UNMC HRPP Policies to be followed by institution investigators

      1. Process of informed consent, including remote consent and electronic signature, documentation of consent and use of Short Form; per HRPP policies 5.1 (Obtaining Informed Consent From Research Subjects), 5.3 (Use of a Remote Consent Process), and 5.5 (Use of the Short Form Consent Document)

      2. WhatResearch willData happenPrivacy, ifConfidentiality, youuse decideof toPHI, stopand participatingData onceSafety youMonitoring; start?per YouHRPP canpolicies stop3.2 participating(Data and Safety Monitoring), 3.3 (Privacy Interests and Confidentiality of Research Data, and 3.4 (Use of Protected Health Information in thisResearch).

        research

      3. Subject Identification and Recruitment, including Ethical Access; per HRPP policies 3.5 (withdraw)Subject atRecruitment anythrough time.Advertisements), Please3.6 tell(Subject theRecruitment Principalthrough Direct Invitation), 3.7 (Finder’s Fees and Recruitment Bonuses), and 3.12 (Ethical Access)

      4. Subject payment; per HRPP policy 3.8 (Research Subject Compensation)

      5. Pregnancy testing, pregnant partner, and contraception; per HRPP policies 3.9 (Contraception Requirements) and 3.10 (Pregnancy Testing).

      6. Investigator or any of theand research staff iftraining; youper wantHRPP topolicy withdraw.1.23 The(HRPP investigatorTraining mayRequirements askand youOpportunities tofor haveResearch somePersonnel)

        additional
        7. tests
      7. done.

        Research Youinvolving dosubjects NOTwith haveimpaired todecision-making agreecapacity; toper doHRPP thesepolicy tests.4.6 (IRB Review of Research Involving Subjects with Impaired Decision-Making Capacity).

      Deciding to withdraw will otherwise not affect your care or your relationship with the investigator or this institution. You will not lose any benefits or care that you would have gotten if you weren’t in the research study.

      OR

      You can stop participating in this research (withdraw) at any time. Please tell the Principal Investigator or any of the research staff if you want to withdraw. They will advise you how to safely stop taking any study drugs or treatments. If you withdraw the investigator may ask you to have some additional tests done. You do NOT have to agree to do these tests.

      Deciding to withdraw will otherwise not affect your care or your relationship with the investigator or this institution. You will not lose any benefits or care that you would have gotten if you weren’t in the research study.

    Back to top